Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-V106 sequential booster vaccination study in previously vaccinated adults
ChiCTR2200067246Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of WSK-V106 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Incidence of adverse reactions within 14 days after each booster vaccination, Incidence of adverse reactions from first dose to 30 days after second booster vaccination and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
WSK-V106
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200067246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067246.